A victim of its own progress: why the success of modern therapeutics forces a re-evaluation of placebo-controlled trials in migraine prevention
By
Nirit Lev
Leah Borovoi
Emily Elefant
Erel Domany
Oved Daniel
Gal Ifergane
July 9, 2026
Clinical Scorecard: Reassessing Placebo-Controlled Trials in Migraine Prevention: The Impact of Advancements in Modern Therapeutics
At a Glance
Category Detail
Condition Migraine Key Mechanisms CGRP-directed monoclonal antibodies and gepants for prevention Target Population Individuals with frequent migraines Care Setting Clinical trials for migraine prevention
Key Highlights
Migraine is a leading cause of years lived with disability. CGRP-targeting therapies are now considered first-line for migraine prevention. Placebo-controlled trials may no longer be ethically justified in migraine prevention. Access to effective treatments varies significantly by region. Ethical guidelines for placebo use require careful justification. Guideline-Based Recommendations
Diagnosis
Management
CGRP-targeting therapies should be considered first-line without prior failure of other preventives. Monitoring & Follow-up
Risks
Placebo exposure may pose ethical concerns when effective treatments are available. Patient & Prescribing Data
Patients with frequent migraines seeking preventive treatment.
Access to CGRP therapies may be restricted based on prior treatment failures.
Clinical Best Practices
Ensure informed consent regarding the use of placebo in trials. Minimize the duration of placebo exposure. Implement robust safety monitoring and interim analyses. Related Resources & Content
